Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$18.66 - $38.58 $243,942 - $504,356
13,073 New
13,073 $502,000
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $471,747 - $704,436
37,470 New
37,470 $655,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.